Top

Top Artificial Intelligence Scientist Eric Xing Joins XtalPi Advisory Broad

Top Artificial Intelligence Scientist Eric Xing Joins XtalPi Advisory Broad

 

Top Artificial Intelligence Scientist Eric Xing Joins XtalPi Advisory Broad

 

Boston, MA (June 8, 2017) – Today, XtalPi announced that Eric P. Xing, a professor at Carnegie Mellon University and a top researcher in artificial intelligence (AI), is joining the company’s advisory board.

 

“Professor Xing is well known for his groundbreaking work in AI and machine learning. We are honored to have him as an advisor,” said Dr. Shuhao Wen, Founder of XtalPi. “His expertise will help us tremendously in our pursuit of using AI to increase pharmaceutical R&D efficiency and expanding the impactful benefit of computational technologies to different areas and stages of pharmaceutical research.”

 

“XtalPi has always emphasized on introducing physics insights to increase the accuracy of existing algorithm models, and we have accumulated much successful experience in optimizing cloud-supercomputing architecture and performance,” said Dr. Wen. “The integration of AI technology will further expand our model’s advantage in speed and efficiency without compromising its accuracy.”

 

The team at XtalPi consists of scientists in quantum physics and chemistry, pharmaceutical R&D, artificial intelligence, big data, and cloud supercomputing. Its drug solid form screening and designing platform is currently in use by top global pharmaceutical clients. By integrating machine learning, it expects to further increase the algorithms’ efficiency and flexibility. XtalPi is also expanding the use of its technologies into other areas across the pharmaceutical value chain, including early drug designing and lead optimization, and drug solubility and toxicity prediction and screening.

 

“One of the advantages of our drug solid form screening and designing algorithms is their high accuracy in generating tens of millions of drug crystal structure data,” sai